




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 471/04, A61K 31/435 // (C07D 471/04, 221:00, 209:00) (C07D 471/04, 231:00, 221:00)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 95/34563 (43) International Publication Date: 21 December 1995 (21.12.95)</p>
<p>(21) International Application Number: PCT/IB95/00373 (22) International Filing Date: 18 May 1995 (18.05.95) (30) Priority Data: 08/260,055 16 June 1994 (16.06.94) US (60) Parent Application or Grant (63) Related by Continuation US 08/260,055 (CON) Filed on 16 June 1994 (16.06.94) (71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): CHEN, Yuhpyng, L. [US/US]; 8 Waterview Drive, Waterford, CT 06385 (US). (74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).</p>		<p>(81) Designated States: AU, CA, CN, CZ, FI, HU, JP, KR, MX, NO, NZ, PL, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.</p>
<p>(54) Title: PYRAZOLO AND PYRROLOPYRIDINES</p> <p>(57) Abstract</p> <p>This invention relates to compounds of formula (I), wherein A is N or -CT₆; B is -NR₁R₂, -CR₁R₂R₁₁, -C(=CR₂R₁₂)R₁, -NHCHR₁R₂, -OCHR₁R₂, -SCHR₁R₂, -CHR₂OR₁₂, -CHR₂SR₁₂, -C(S)R₁ or -C(O)R₁. The compounds show corticotropin-releasing factor (CRF) antagonist activity. CRF antagonists are believed to be effective in the treatment of a wide range of stress-related illnesses, such as depression, anxiety, headache, irritable bowel syndrome, inflammatory diseases, immune suppressin, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, drug and alcohol withdrawal symptoms, drug addiction and infertility.</p> <div style="text-align: right;">  <p>(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

PYRAZOLO AND PYRROLOPYRIDINES

5

Background of the Invention


This invention relates to pyrazolopyridines and pyrrolopyridines, pharmaceutical compositions containing them, and methods of administering them to subjects in need of their corticotropin-releasing factor (CRF) antagonist activity.

10 CRF antagonists are mentioned in U.S. Patents 4,605,642 and 5,063,245 referring to peptides and pyrazolinones, respectively. The importance of CRF antagonists is referred to in the literature, e.g., as discussed in U.S. Patent 5,063,245, which is incorporated herein by reference. A recent outline of the different activities possessed by CRF antagonists is found in M. J. Owens *et al.*, *Pharm. Rev.*, Vol. 43, 15 pages 425 to 473 (1991), also incorporated herein by reference. Based on the research described in these and other references, CRF antagonists are believed to be effective in the treatment of a wide range of stress-related illnesses, such as depression, anxiety, headache, irritable bowel syndrome, inflammatory diseases, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, hemorrhagic stress, 20 drug and alcohol withdrawal symptoms, drug addiction and infertility.

Summary of the Invention

The present invention relates to a compound of the formula

25



30 and the pharmaceutically acceptable acid addition salts thereof, wherein

A is N or $-\text{CR}_6$;

B is $-\text{NR}_1\text{R}_2$, $-\text{CR}_1\text{R}_2\text{R}_{11}$, $-\text{C}(=\text{CR}_2\text{R}_{12})\text{R}_1$, $-\text{NHCHR}_1\text{R}_2$, $-\text{OCHR}_1\text{R}_2$, $-\text{SCHR}_1\text{R}_2$, $-\text{CHR}_2\text{OR}_{12}$, $-\text{CHR}_2\text{SR}_{12}$, $-\text{C}(\text{S})\text{R}_1$ or $-\text{C}(\text{O})\text{R}_1$;

R_i is C_1 - C_6 alkyl which may optionally be substituted with one or two 35 substituents independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C_1 - C_4 alkoxy, $-\text{O}-\text{CO}-(\text{C}_1-\text{C}_4 \text{ alkyl})$, $-\text{O}-\text{CO}-\text{NH}(\text{C}_1-\text{C}_4 \text{ alkyl})$, $-\text{O}-\text{CO}-\text{N}(\text{C}_1-\text{C}_4 \text{ alkyl})(\text{C}_1-\text{C}_2 \text{ alkyl})$, $-\text{NH}(\text{C}_1-\text{C}_4 \text{ alkyl})$, $-\text{N}(\text{C}_1-\text{C}_2 \text{ alkyl})(\text{C}_1-\text{C}_4 \text{ alkyl})$, $-\text{S}(\text{C}_1-\text{C}_4 \text{ alkyl})$,

-2-

-N(C₁-C₄ alkyl)CO(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), CN, NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), and wherein any of the foregoing C₁-C₄ alkyl and C₁-C₆ alkyl groups may optionally contain one carbon-carbon double or triple bond;

- 5 R₂ is C₁-C₁₂ alkyl, aryl, -(C₁-C₄ alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, oxazolyl, or benzoxazolyl; or 3- to 8- membered cycloalkyl or -(C₁-C₆ alkylene)cycloalkyl, wherein
 10 one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C₁-C₆ alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N-Z wherein Z is hydrogen; or C₁-C₄ alkyl, and wherein each of said groups R₂ may optionally be substituted with from one to three substituents independently selected from chloro,
 15 fluoro, and C₁-C₄ alkyl, or by one substituent selected from bromo, iodo, C₁-C₆ alkoxy, -O-CO-(C₁-C₆ alkyl), -S(C₁-C₆ alkyl), -COO(C₁-C₄ alkyl), CN, NO₂, -SO(C₁-C₄ alkyl), and -SO₂(C₁-C₄ alkyl), and wherein said C₁-C₁₂ alkyl and the C₁-C₄ alkylene moiety of said -(C₁-C₄ alkylene)aryl may optionally contain one carbon-carbon double or triple bond;
 or -NR₁R₂ may form a saturated 5- to 8-membered heterocyclic ring, or -CHR₁R₂
 20 may form a saturated 5- to 8-membered carbocyclic ring, wherein each of these rings may optionally contain one or two carbon-carbon double bonds and wherein one or two of the carbon atoms of each of these rings may optionally be replaced with a sulfur or oxygen atom;

- R₃ is C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, -CH₂OH, -CH₂OCH₃, -O(C₁-C₃
 25 alkyl), -S(C₁-C₃ alkyl), or -SO₂(C₁-C₃ alkyl), wherein said C₁-C₃ alkyl may optionally contain one carbon-carbon double or triple bond;

- R₄ is hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, amino, -NHCH₃, -N(CH₃)₂, -CH₂OH, -CH₂OCH₃, or -SO_n(C₁-C₄ alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, -CO(C₁-C₄ alkyl), -CHO, or -COO(C₁-C₄ alkyl) wherein the C₁-C₄ alkyl
 30 moieties in the foregoing R₄ groups may optionally contain one carbon-carbon double or triple bond;

 R₅ is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, pyrimidyl, benzofuranyl, pyrazinyl or benzothiazolyl, wher in each one of said groups R₅ may optionally b

-3-

substituted with from one to three substituents independently selected from fluoro, chloro, C₁-C₆ alkyl and C₁-C₆ alkoxy, or by one substituent selected from iodo, hydroxy, bromo, formyl, cyano, nitro, amino, trifluoromethyl, -NH(C₁-C₄ alkyl), -N(C₁-C₆)(C₁-C₂ alkyl), -COO(C₁-C₄ alkyl), -CO(C₁-C₄ alkyl), -COOH, -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -SO₂NH₂, -NHSO₂(C₁-C₄ alkyl), -S(C₁-C₆ alkyl) and -SO₂(C₁-C₆ alkyl),
 5 wherein each of said C₁-C₄ alkyl and C₁-C₆ alkyl moieties in the foregoing R₅ groups may optionally be substituted with one to three fluorine atoms;

R₆ is hydrogen, C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, -CH₂OH, -CH₂OCH₃, or C₁-C₄ alkoxy;

10 R₇ is hydrogen, C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, -O(C₁-C₄ alkyl), cyano, -CH₂OH, -CH₂O(C₁-C₂ alkyl), -CO(C₁-C₂ alkyl), or -COO(C₁-C₂ alkyl);

R₁₁ is hydrogen, hydroxy, fluoro, or methoxy; and

R₁₂ is hydrogen or C₁-C₄ alkyl;

with the proviso that when A is N, then: (a) B is not unsubstituted alkyl; (b) R₅
 15 is not unsubstituted phenyl; and (c) R₃ is not unsubstituted alkyl.

More specific embodiments of this invention relate to compounds of the formula I wherein B is -NR₁R₂, -NHCHR₁R₂, -CR₁R₂R₁₁, -SCHR₁R₂ or -OCHR₁R₂; R₁ is C₁-C₄ alkyl, which may optionally be substituted with one hydroxy, fluoro or C₁-C₂ alkoxy group and may optionally contain one carbon-carbon double or triple bond; R₂ is benzyl or C₁-C₆
 20 alkyl which may optionally contain one carbon-carbon double or triple bond, wherein said C₁-C₆ alkyl or the phenyl moiety of said benzyl may optionally be substituted with fluoro, C₁-C₂ alkyl, or C₁-C₂ alkoxy; and R₁₁ is hydrogen or fluoro.

Other more specific embodiments of this invention relate to compounds of the formula I wherein B is tetrahydrofuranyl, tetrahydrothienyl or thiazolidinyl.

25 Other more specific embodiments of this invention relate to compounds of the formula I wherein: (a) R₁ and R₂ are each, independently, C₁-C₄ alkyl which may optionally be substituted with fluoro, C₁-C₂ alkyl or C₁-C₂ alkoxy and which may optionally contain one carbon-carbon double or triple bond; or (b) R₁ is C₁-C₄ alkyl substituted with hydroxy.

30 Other more specific embodiments of this invention relate to compounds of the formula I wherein: (a) R₃ is methyl, chloro, or methoxy; (b) R₄ and R₆ are each, independently, hydrogen, methyl, ethyl, or chloro, and R₄ and R₆ are not both hydrogen; and (c) R₅ is phenyl substituted by two or three substituents independently

-4-

selected from fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, trifluoromethyl, C₁-C₆ alkyl which may optionally be substituted by one of hydroxy, C₁-C₄ alkoxy and fluoro and may optionally have one double or triple bond, -(C₁-C₄ alkylene)O(C₁-C₂ alkyl), C₁-C₃ hydroxyalkyl, hydroxy, formyl, -COO(C₁-C₂ alkyl), and -(C(O)(C₁-C₄ alkyl).

5 Other more specific embodiments of this invention relate to compounds of the formula I wherein R₃ is methyl, ethyl halo, methoxy or thiomethyl, R₄ is hydrogen, C₁-C₃ alkyl, halo, thiomethyl, sulfanylmethyl, sulfonylmethyl or methoxy and R₅ is substituted phenyl, substituted pyridyl or substituted pyrimidyl.

Examples of specific compounds of this invention are:

10 butyl-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-ethylamine;

3,6-dimethyl-4-(tetrahydrofuran-3-yloxy)-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine

15 [3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4,b]pyridin-4-yl]-(1-methoxymethylpropyl)-amine;

4-(1-methoxymethylpropoxy)-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine;

(1-ethylpropyl)-[3,5,6-trimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-amine;

20 4-(1-ethylpropoxy)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-b]pyridine;

4-(1-ethylpropoxy)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-b]pyridine; and

25 4-(1-ethylpropoxy)-2,5-dimethyl-7-(2,6-dimethyl-4-bromophenyl)-7H-pyrrolo[2,3-b]pyridine.

Compounds of the formula I wherein R₅ is substituted with one substituent selected from hydroxymethyl, -CH₂O(C₁-C₆ alkyl) and CH₂OCF₃ are also CRF antagonists and are useful in the treatment of the disorders enumerated in the following two paragraphs.

30 The invention also relates to a pharmaceutical composition for the treatment of (a) a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, or (b) a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis,

-5-

pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; dysthymia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome, Crohn's disease; spastic colon; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; chemical dependencies and addictions (e.g., dependencies on alcohol, cocaine, heroin, benzodiazepines, or other drugs); drug and alcohol withdrawal symptoms; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g., porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; and hypoglycemia in a mammal, including a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in the treatment of such disorder, and a pharmaceutically acceptable carrier.


25 The invention further includes a method for the treatment of (a) a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitator by CRF, or (b) a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; dysthymia; bipolar disorders;

30

-6-

cyclothymia; fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome; Crohn's disease; spastic colon; human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g., porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; chemical dependencies and addictions (e.g., dependencies on alcohol, cocaine, heroin, benzodiazepines, or other drugs); drug and alcohol withdrawal symptoms; and hypoglycemia in a mammal, including a human, comprising administering to a subject in need of said treatment an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder.

The invention further includes intermediate compounds of the formula



wherein D is chloro, hydroxy or cyano, R₁₉ is methyl, ethyl or chloro, and A, R₄, R₅ and R₇ are as defined above with reference to formula I.

Detailed Description of the Invention

As used herein, unless otherwise indicated, the term "C₁-C₆ alkyl", refers to a straight or branched chain alkyl of one to six carbon atoms, such as methyl, ethyl, isopropyl, t-butyl or hexyl.

-7-

Whenever reference is made herein to 3- to 8-membered cycloalkyl containing one or two of O, S or N-Z, it is understood that the oxygen and sulfur ring atoms are not adjacent to each other. An example of a six-membered cycloalkyl having O and N is morpholinyl.

5 Whenever R_2 or R_5 is a heterocyclic group, the point of attachment of such group is through a carbon atom.

Whenever reference is made herein to C_1 - C_4 alkyl or C_1 - C_6 alkyl which "may contain one double or triple bond" in the definitions of R_1 , R_2 and R_3 , it is understood that at least two carbons are present in the alkyl group.

10 As used herein, unless otherwise indicated, the terms "halo", "halogen" and "Hal" refer to fluoro, chloro, bromo or iodo.

Compounds of the formulae I and II may contain chiral centers and therefore many exist in different enantiomeric forms. This invention relates to all optical isomers and stereoisomers of compounds of the formulae I and II and to mixtures thereof.

15 Compounds of the formula I wherein B is $-NR_1R_2$, $-NHCHR_1R_2$, $-OCHR_1R_2$, or $-SCHR_1R_2$, and R_3 is C_1 - C_4 alkyl or chloro may be prepared by reaction of a compound of the formula II wherein D is Cl, and R_4 , R_5 , R_7 and A are as defined above with reference to formula I, with a compound of the formula BH wherein B is as defined immediately above or with a compound of the formula R_1NH_2 . The reaction is carried
20 out in a solvent in the presence of a base at a temperature between about room temperature and about 230°C, with or without an organohalide such as copper bromide, iodide or chloride, or magnesium bromide, or with or without an acid catalyst such as p-toluene sulfonic acid. Suitable solvents are organic solvents such as tetrahydrofuran (THF), acetonitrile, dimethylsulfoxide (DMSO), acetone, C_2 - C_5 alkyl
25 alcohol, chloroform, benzene, xylene, dioxane, toluene, sulfolane, pyridine, or 1-methyl-2-pyrrolidinone. The solvent is preferably dimethylsulfoxide or 1-methyl-2-pyrrolidinone.

When B in the desired compound of formula I is $-NR_1R_2$ or $-NHCHR_1R_2$, an excess of BH may be used as a reagent and a base. Bases other than BH, such as potassium carbonate and tri- $(C_1$ - $C_6)$ alkylamine may also be used. This reaction is
30 generally carried out at a temperature from about 75° to about 230°C. An organohalide such as copper bromide may be added to facilitate the reaction. When the reaction is very inert, compounds of the formula I wherein B is $-NR_1R_2$ or $-NHCHR_1R_2$ can be prepared by a two step reaction, as described below. Reaction of

-8-


compounds of formula II with an excess of R_1NH_2 or NH_3 or an equivalent NH_3 precursor (e.g., NaN_3 , $nBu_4N^+N_3^-$ or NH_2OH) at temperature from about $75^\circ C$ to about $250^\circ C$ and at a pressure from about 0 to about 300 psi, in an appropriate solvent as described above, yields compounds of formula I wherein B is $-NHR_1$, $-NH_2$, $-NH_2OH$ or $-N_3$. Conversion of compounds of formula I wherein B is $-N_3$ or $-NH_2OH$ into the corresponding compounds of formula I wherein B is $-NH_2$ can be accomplished by methods known in the art such as hydrogenation or reduction. Alkylation of compounds of formula I wherein B is $-NHR_1$ or $-NH_2$ with an appropriate alkyl halide in the presence of an appropriate base such as lithium or sodium bistrimethylsilylamide or lithium or sodium diisopropylamide or n-butyllithium or potassium t-butoxide, in an appropriate solvent such as THF, dioxane or methylene chloride, will give the corresponding compounds of formula I wherein B is $-NR_1R_2$. Alternatively, acylation of compounds of formula I wherein B is $-NHR_1$ or $-NH_2$, followed by reduction with a borohydride (e.g., sodium borohydride) will give compounds of formula I wherein B is $-NR_1R_2$.

Alternatively, when the reaction of BH and the appropriate compound of formula II is very inert, acidic conditions obtained with p-toluenesulfonic acid or phenol or its derivatives may be used.

When B is $-OCHR_1R_2$ or $-SCHR_1R_2$, a base which is capable of deprotonating BH may be used, such as an alkali metal hydride such as sodium or potassium hydride, or an organometallic base such as sodium diisopropylamide, sodium bis(trimethylsilyl)amide, lithium diisopropylamide, lithium or sodium bis(trimethylsilyl)amide or n-butyllithium. The solvent is preferably tetrahydrofuran, dimethylsulfoxide, methylene chloride, toluene, sulfolane or 1-methyl-2-pyrrolidinone, and the reaction is typically carried out between about room temperature and $180^\circ C$, preferably between about $50^\circ C$ and about $130^\circ C$.

The compounds of formula I wherein B is $-CR_1R_2R_{11}$, $-C(C=CR_2R_{12})R_1$, $-CHR_2OR_{12}$, $-CHR_2SR_{12}$, $-C(S)R_1$ or $-C(O)R_1$, and R_3 is chloro or (C_1-C_4) alkyl may be prepared as depicted in Scheme I.

SCHEME 1



Compounds of the formula II wherein D is cyano, R_4 , R_5 and R_7 are as defined
 25 above and R_9 is (C_1-C_4) alkyl or chloro (hereinafter referred to as compounds of the
 formula IIA), may be prepared by reacting the corresponding compounds of the formula
 II wherein D is chloro with potassium cyanide or copper cyanide with or without a
 sodium p-toluenesulfonate or sodium methanesulfonate catalyst in dimethylsulfoxide
 or N,N-dimethylformamide. These compounds (IIA) are then reacted with a Grignard
 30 reagent containing the group R_1 , as defined above, to form compounds of the formula
 IA wherein Q is O. Compounds of the formula IA wherein Q is S may be prepared by
 reacting the corresponding compounds of formula IA wherein Q is O with Lawesson's
 Reagent or by another method well known to those skilled in the art. Reaction of the

-10-

compounds of formula IA wherein Q is O with a Grignard reagent containing group R_2 , as defined above, provides the corresponding compounds of formula IB. The corresponding compounds of the formula IC wherein B is $-CR_1R_2R_{11}$ or $-C(C=CR_2R_{12})R_1$ may be prepared by conventional methods well known to those skilled in the art. Thus,

5 reaction of a compound of the formula IB with an acid, such as concentrated sulfuric acid in acetic acid, or Burgess inner salt, such as (carboxysulfamoyl)triethylammonium hydroxide methyl ester, gives a compound of the formula IC wherein B is $-C(=CR_2R_{12})R_1$. Hydrogenation of a compound of the formula IC wherein B is $-C(=CR_2R_{12})R_1$ using a palladium/carbon or platinum oxide catalyst gives a compound

10 of the formula IC wherein B is $-CHR_1R_2$. Reaction of compound of the formula IB with diethylaminosulfur trifluoride or triphenylphosphine together with carbon tetrachloride, carbontetrabromide, or iodine affords a compound of the formula IC wherein B is $-CR_1R_2F$ or $-CR_1R_2Hal$, respectively. Reduction of a compound of the formula IA with sodium borohydride gives a compound of the formula I wherein B is $-CHR_1OH$.

15 Alkylation of this $-CHR_1OH$ group with an alkyl halide such as alkyl iodide in the presence of a base such as sodium hydride at room temperature affords a compound of the formula I wherein B is $-CHR_2OR_1$.

Compounds of the formula II wherein A is N, D is OH and R_9 is C_1 - C_4 alkyl may be prepared, as shown in Scheme 2, by reacting a compound of the formula IV with

20 a compound of the formula III in the presence of an acid catalyst, such as p-toluenesulfonic acid, HCl, or H_2SO_4 , in an appropriate solvent such as toluene, benzene or xylene, under Dean-Stark trap conditions at a temperature between about 60 and $150^\circ C$, preferably at reflux. Similarly, when $ClC(O)CH(R_7)COO(C_1-C_4 \text{ alkyl})$ is used instead of a compound of the formula III, the corresponding compound wherein R_9 is

25 OH is obtained. Conversion of compounds wherein R_9 is OH to Cl can be accomplished by reaction with a chlorinating agent such as $POCl_3$ in the presence of a base such as N-diethylaniline. Compounds of the formula IV can be obtained by acid hydrolysis of the corresponding compounds of the formula V at the reflux temperature. Examples of suitable acids are 85% phosphoric acid, aqueous HCl and aqueous


30 H_2SO_4 . Compounds of the formula V may be prepared by the methods disclosed in corresponding patent application Serial No. PCT/US 93/11333, which designated the United States and was filed on November 26, 1993, or by procedures known to those skilled

-11-

in the art. World Patent Application PCT/US 93/11333 is incorporated herein by reference in its entirety.

-12-

SCHEME 2




Compounds of the formula II wherein A is $-CR_6$ and R_9 is C_1-C_4 alkyl may be prepared as shown in Scheme 3. Compounds of the formula VII wherein R_7 is $-COOR$, CN , or $-CO-(C_1-C_2 \text{ alkyl})$, may be prepared by heating compounds of the formula VI with $R_9C(O)CHR_7$, wherein R^9 is chloro or $(C_1-C_4)\text{alkyl}$, in an appropriate solvent such as toluene, xylene, or benzene, in the presence of acid catalyst such as p-toluenesulfonic acid, sulfuric acid or gaseous HCl at a temperature between about $80^\circ C$ and $150^\circ C$, preferably at the reflux temperature under a Dean-stark trap to remove water, followed by cyclization. The cyclization may be performed under acidic conditions such as 85% to 100% phosphoric acid or sulfuric acid at reflux, or under basic conditions such as sodium ethoxide in ethanol or sodium hydride (NaH) in THF or DMSO, at a temperature between about $25^\circ C$ and $100^\circ C$. Conversion of compounds of formula VII to compounds of the formula IIB wherein D is OH may be accomplished by methods well known in the art.

Compounds of the formula I wherein R_7 is other than $-COOR$, $-COR$ or CN may be prepared through an intermediate of the formula IIB or a compound of the formula ID, wherein R_7 is $-COOR$, $-COR$ or CN , as shown in Scheme 3, by conversion of the R_7

-13-

group to other R_7 groups using general organic methods known in the art. For example, hydrolysis of a compound wherein R_7 is an ester with a base (e.g., lithium hydroxide in 1:1 water:dioxane or 1:1 water:methanol or aqueous LiOH or NaOH) at a temperature between about 80°C and 100°C, followed by quenching with an acid and heating at the reflux temperature to accomplish decarboxylation gives the corresponding compound of the formula ID wherein R_7 is H. Reduction of compounds wherein R_7 is an ester group with a reducing agent such as LiAlH_4 or diisobutylaluminum hydride affords the corresponding compounds wherein R_7 is CH_2OH or CHO. Alkylation of the CH_2OH group with a base such as NaH, sodium alkoxide or organolithium agents, followed by alkylation with methyl iodide or ethyl iodide gives the compounds of the formula ID wherein R_7 is $-\text{CH}_2\text{OCH}_3$ or $-\text{CH}_2\text{OC}_2\text{H}_5$. Grignard reaction of $-\text{CO}_2\text{CH}_3$, $-\text{CO}_2\text{C}_2\text{H}_5$, $-\text{COCH}_3$ or $-\text{COC}_2\text{H}_5$, followed by elimination and hydrogenation gives compounds of the formula ID wherein R_7 is an alkyl group. Compounds of the formula IIB or ID wherein R_7 is CH_2OH may be converted into the corresponding compounds wherein R_7 is CH_2Cl or CH_2F as follows. Reaction of HCOCH_3 with a peracid, followed by hydrolysis gives the corresponding compound wherein R_7 is hydroxy. Reaction of the hydroxy group with a base, followed by quenching with a C_1 - C_4 alkyl halide gives the corresponding compound wherein R_7 is $-\text{O}(\text{C}_1\text{-C}_4 \text{ alkyl})$. Conversion of compounds wherein R_7 is hydroxy into those wherein R_7 is halo may be performed by conventional methods. In the above synthetic sequence, a protecting or deprotecting method may be required to achieve the desired compounds.


-14-

SCHEME 3

-15-

An alternative method for preparing compounds of the formula II B wherein D is hydroxy, chloro or cyano is shown below in Scheme 4.

SCHEME 4



Compounds of the formula VIII wherein L and L' are suitable leaving groups, such as chloro, bromo, mesyl, tosyl or methoxy, may be converted into a compound of the formula IX wherein D is hydroxy or L' by reaction with an amine of the formula R_5NH_2 in the presence of a catalytic amount of an acid such as p-toluenesulfonic acid or sulfuric acid or a base which is capable of deprotonating R_5NH_2 such as n-butyllithium or an organohalide such as copper bromide, chloride or iodide, or magnesium bromide. The reaction may be carried out with or without a suitable solvent such as an alcohol (e.g., pentanol), DMSO, sulfolane or dioxane. Alkylation of the compounds of formula IX to introduce R_4 may be carried out by conventional methods. Preferably, the process is carried out by first adding a base, such as sodium or potassium hydride, to a compound of the formula IX contained in an inert solvent, such as an ether, e.g., diethylether, THF or dioxane, or a polar aprotic solvent such as DMSO, under an inert atmosphere, e.g., nitrogen, followed by addition of a compound of the formula R_4L wherein L is as defined above. The reaction temperature is preferably between about 0°C and about 25°C. When R_4 is halogen, R_4L is a halogenating agent such as bromine, chlorine, iodine, diethylaminosulfurtrifluoride or N-bromosuccinimide. Compounds of the formula X wherein R_4 is thiophenyl, which may be prepared by reacting compounds of formula IX with phenyl-S-SO_n-phenyl wherein n is 0, 1 or 2, may be converted into compounds of the formula X wherein R_4 is C₁-C₆ alkyl by reaction with C₁-C₆ alkyl iodide, followed by reduction of the thiophenyl group with Raney nickel or trimethylsilylchloride (TMSCl) with zinc to provide a selective monosubstituted compound of the formula X.

-16-

Compounds of the formula IIB wherein R_6 is hydrogen may be formed from compounds of the formula X by reduction, e.g., with lithium aluminum hydride or diisobutyl aluminum hydride, followed by elimination or dehydrogenation. Reaction of compounds of the formula X by organometal addition, e.g., by reaction with dialkyl zinc, dialkylaluminum hydride or Grignard reagents containing group R_6 , followed by hydrolysis or dehydrogenation, provides compounds of the formula IIB wherein R_6 is other than hydrogen. Reaction of compounds of the formula X with a halogenating agent such as POCl_3 , SOCl_2 , PCl_3 , or triphenylphosphine with iodine in the presence of a base such as pyridine gives compounds of the formula IIB wherein R_6 is halogen.

5 Reaction of compounds of the formula X with a base such as a trialkylamine, sodium hydride or pyridine, followed by quenching with a dialkyl sulfate or a $\text{C}_1\text{-C}_4$ alkyltrifluoromethanesulfonate in an appropriate solvent such as hexamethylphosphoramide, affords compounds of the formula IIB wherein R_6 is $-\text{O}(\text{C}_1\text{-C}_4)$ alkyl.

10

Compounds of the formula I, wherein B is as defined with reference to formula I and R_3 is other than chloro or $(\text{C}_1\text{-C}_4)$ alkyl, may be prepared by reacting a compound of the formula I wherein R_3 is chloro with a nucleophile of the formula R_{10}H , wherein R_{10} is defined as R_3 except that it cannot be chloro or $(\text{C}_1\text{-C}_4)$ alkyl, with or without an organic or inorganic base. Suitable bases include sodium and sodium hydride when R_{10}H is an alkanol or an alkane thiol, and weaker bases such as potassium carbonate or triethylamine when R_{10}H is an amine. Compounds of the formula I wherein R_{10} is fluoro may be prepared from the corresponding compounds wherein R_3 is chloro by reaction with tetrabutylammonium fluoride. Suitable solvents for this reaction include dimethylsulfoxide, tetrahydrofuran and methylene chloride. The solvent is preferably tetrahydrofuran.

15

20

25 The acid addition salts are prepared in a conventional manner by treating a solution or suspension of the free base of a compound of the formula I with one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration or crystallization techniques are employed in isolating the salts. Illustrative of suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzene sulfonic, p-toluenesulfonic, and related acids.

30

-17-

The active compounds of this invention (compounds of the formula I and their pharmaceutically acceptable salts) may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. The pharmaceutical compositions formed by combining the novel compounds of formula I and pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, methylcellulose, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.

For parenteral administration, solutions of an active compound of this invention in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

The effective dosage for the active compounds of this invention depends on the intended route of administration and other factors such as age and weight of the patient, as generally known to a physician. The dosage also depends on the illness to be treated. The daily dosage for stress-induced illnesses will generally range from

-18-

about 0.1 to 50 mg/kg of the body weight of the patient to be treated, for treatment of inflammatory diseases about 0.1 to about 50 mg/kg will be needed, for Alzheimer's disease, about 0.1 to about 50 mg/kg, for gastrointestinal diseases about 0.1 to about 50 mg/kg, for anorexia nervosa about 0.1 to about 50 mg/kg, for hemorrhagic stress
5 about 0.1 to about 50 mg/kg, for drug and alcohol withdrawal symptoms, about 0.1 to about 50 mg/kg.

The active compounds of this invention will generally be administered from one to three times per day (i.e., from one to three doses per day), with each dose containing from about 0.1 to about 100 mg/kg body weight, although variations will
10 necessarily occur depending upon the weight and condition of the subject being treated, the nature and severity of the disorder for which the subject is being treated and the particular route of administration chosen. However, a dosage level that is in the range of about 1.0 mg to about 50 mg per kg of body weight per individual dose will most desirably be employed. Variations may nevertheless occur depending upon
15 the species of mammal being treated and the individual subject's response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out.

Methods for determining the CRF antagonist activity of compounds of the formula I and their pharmaceutically acceptable salts are described in Endocrinology,
20 116, 1653-1659 (1985) and Peptides, 10, 179-188 (1985). The binding activities for the compound of formula I, expressed as IC_{50} values, generally range from 0.5 nanomolar to about 10 micromolar.

The following Examples illustrate the preparation of the compounds of the present invention. Melting points are uncorrected. NMR data are reported in parts per million (δ) and are referenced to the deuterium lock signal from the sample solvent (deuteriochloroform unless otherwise specified). Specific rotations were measured at
25 room temperature using the sodium D line (589 nm). Commercial reagents were utilized without further purification. THF refers to tetrahydrofuran. DMF refers to dimethylformamide. Chromatography refers to column chromatography performed
30 using 32-63 μ m silica gel and executed under nitrogen pressure (flash chromatography) conditions. Room or ambient temperature refers to 20-25°C. All non-aqueous reactions were run under a nitrogen atmosphere for convenience and to maximize yields. Concentration at reduced pressure implies the use of a rotary evaporator.

Example 1(1-Ethylpropyl)-[3,5,6-trimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-amine

- A mixture of 4-chloro-3,5,6-trimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin (227 mg, 0.72 mmol), p-TsOH (124 mg) and ethylpropylamine (0.5 ml) in 1 ml of dimethylsulfoxide (DMSO) was heated at reflux for 4 hours (thin layer chromatography showed no reaction). Copper bromide (40 mg) was added and the reaction was heated for an additional 15 hours at reflux. The reaction mixture was quenched with saturated ammonium chloride and extracted with ethyl acetate (EtOAc).
- 10 The organic layer was washed with brine, dried and concentrated to give a brown oil. The oil residue was purified through silica gel column chromatography using chloroform (CHCl₃) and hexane in a ratio of 8:3 as eluent to give the title compound as a colorless oil. ¹H NMR (CDCl₃) 6.92 (s, 2H), 3.97 (d, 1H, NH), 3.56 (brs, 1H, OH), 2.70 (s, 3H), 2.43 (s, 3H), 2.29 (s, 3H), 2.18 (s, 3H), 1.89 (s, 6H), 1.4 ~ 1.7 (m, 4H), 0.94 (t, 6H) ppm.
- 15 The compound was prepared as the corresponding HCl salt as an off-white crystals after recrystallization from a solvent mixture of ethyl ether and ethyl acetate, mp 201-205°C.

Example 2Butyl-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]ethyl-amine

- A mixture of 4-chloro-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine (98 mg, 0.33 mmol), N-butylethylamine (1 ml) in DMSO (2 ml) was heated in an oil bath at 175-180°C for 20 hours. The reaction mixture was quenched with saturated ammonium chloride and extracted with EtOAc. The organic layer was
- 25 washed with brine, dried, and concentrated to give a brown oil. The oil residue was purified through silica gel column chromatography using EtOAc/Hexane in a ratio of 1/9 as eluent to give a colorless oil. ¹H NMR (CDCl₃) 6.92 (s, 2H), 6.29 (s, 1H), 3.42 (q, 2H), 3.27 (t, 2H), 2.65 (s, 3H), 2.44 (s, 3H), 2.30 (s, 3H), 1.91 (s, 6H), 1.57 (m, 2H), 1.33 (m, 2H), 1.13 (t, 3H), 0.90 (t, 3H) ppm. IR (neat) 2960, 2920, 1570 cm⁻¹. High MS,
- 30 calc. 364.2627, found 364.26306.

-20-

Example 32-[3,6-Dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-ylamino]-butan-1-ol

A mixture of 4-chloro-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine (380 mg, 1.27 mmol), (S)-2-amino-1-butanol (0.9 ml) in DMSO (2 ml) was heated in an oil bath at 190°C for 20 hours. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried, and concentrated to give a brown oil. The oil residue was purified through silica gel column chromatography using EtOAc/Hexane=1/9 as eluent to give 113 mg of the title compound as a yellow oil. ¹H NMR (CDCl₃): 6.9 (s, 2H), 5.95 (s, 1H), 4.94 (d, 1H), 3.70 (m, 2H), 3.52 (m, 1H), 2.62 (s, 3H), 2.40 (s, 3H), 2.28 (s, 3H), 1.92 (s, 3H), 1.90 (s, 3H), 2.6-2.8 (m, 2H), 1.0 (t, 3H) ppm.

Example 42-[3,6-Dimethyl-1-(2,4,6-trimethylphenyl)-1-H-pyrazolo[3,4-b]pyridin-4-ylamino]-butan-1-ol and 3,6-Dimethyl-4-phenoxy-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine

A mixture of 4-chloro-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine (300 mg, 1 mmol), (S)-2-amino-1-butanol (107 mg, 1.2 mmol) and phenol (188 mg, 2 mmol) was heated in 190°C oil bath for 15 hours. The mixture was cooled, quenched with 2 N sodium hydroxide and extracted with chloroform. The organic layer was separated and neutralized with 2 N hydrochloride and water. The organic layer was dried and concentrated to give an oil residue. The residue was purified through silica gel column chromatography using chloroform as eluent to give 157 mg of starting material, and 52 mg of 3,6-dimethyl-4-phenoxy-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine as beige crystals. ¹H NMR (CDCl₃): 7.1-7.45 (m, 5H), 6.95 (s, 2H), 6.06 (s, 1H), 2.71 (s, 3H), 2.38 (s, 3H), 2.29 (s, 3H), 1.94 (s, 6H) ppm; and 30 mg of 2-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1-H-pyrazolo[3,4-b]pyridin-4-ylamino]-butan-1-ol as a yellow glass.

Example 5[3,6-Dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-(1-methoxymethyl-propyl)-amine

A solution of 2-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-ylamino]-butan-1-ol (69 mg, 0.196 mmol) in 1 ml of dry tetrahydrofuran was treated with

-21-

60% sodium hydride oil (28 mg, 0.7 mmol). After stirring for 3 minutes, methyl iodide (0.3 ml) was added and the mixture was stirred at room temperature for 1.5 hours. The mixture was quenched with water and extracted with ether. The organic layer was washed with water, dried and concentrated to give 61 mg of crude material. The residue was purified through silica gel column chromatography using chloroform as eluent to give 43 mg of the title compound in yellow glass form. ¹H NMR (CDCl₃): 6.91 (s, 2H), 6.00 (s, 1H), 5.05 (d, 1H), 3.4-3.6 (m, 2H), 3.41 (s, 3H), 2.66 (s, 3H), 2.40 (s, 3H), 2.28 (s, 3H), 1.92 (s, 3H), 1.91 (s, 3H), 1.6-1.8 (m, 2H), 1.05 (t, 3H), ppm; IR (CHCl₃) 2920, 1586 cm⁻¹; High MS calc. 366.2413, found 3.66.24516. The glass form was converted to the corresponding HCl salt form as a yellow solid.

Example 6

4-(1-Methoxymethyl-propoxy)-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine

Sodium hydride (60% in oil, 94 mg, 1.33 mmol) was washed with hexane and suspended in 2 ml of tetrahydrofuran (THF). 1-Methoxy-2-butanol (0.7 ml) was added and stirred at room temperature for 5 minutes. A solution of 4-chloro-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine (200 mg, 0.665 mmol) in 1 ml of THF was added and the resulting mixture was heated at reflux for 15 hours. The mixture was quenched with water and extracted with EtOAc. The organic layer was dried and concentrated to give 201 mg of crude product as a yellow solid. The solid was purified through silica gel column chromatography using 1% methanol in chloroform as eluent to give 175 mg of off-white crystals, mp 108-108°C; IR (KBr) 2900, 1600, 1580 cm⁻¹; high MS, calc. 367.2253, found, 367.22754; ¹H NMR (CDCl₃): 6.93 (s, 2H), 6.34 (s, 1H), 4.59 (m, 1H), 3.64 (2 sets ABq, 2H), 3.41 (s, 3H), 2.64 (s, 3H), 2.48 (s, 3H), 2.29 (s, 3H), 1.91 (s, 3H), 1.89 (s, 3H) 1.7-1.9 (m, 2H), 1.04 (t, 3H) ppm.

Example 7

3,6-Dimethyl-4-(tetrahydrofuran-3-yloxy)-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine

Sodium hydride (60% in oil, 176 mg, 4.4 mmol) was washed with hexane and suspended in 2 ml of tetrahydrofuran. 3-Hydroxytetrahydrofuran (1 ml) was added and stirred at room temperature for 5 minutes. A solution of 4-chloro-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine (200 mg, 0.665 mmol) in 1 ml of THF was added and the resulting mixture was heated at reflux for 8 hours. The mixture was

-22-

quenched with water and extracted with EtOAc. The organic layer was dried and concentrated to give 334 mg of crude product. The crude material was purified through silica gel column chromatography using 1% methanol in chloroform as eluent to give 127 mg of a beige solid, mp 117-119°C; IR(KBr) 2950, 1600, 1580 cm⁻¹; high MS, calc. 351.1941, found, 351.19386; ¹H NMR (CDCl₃): 6.90 (s, 2H), 6.15 (s, 1H), 5.07 (m, 1H), 3.9-4.05 (m, 4H), 2.6 (s, 3H), 2.47 (s, 3H), 2.38 (s, 3H), 2.2-2.3 (m, 2H), 1.98 (s, 3H), 1.96 (s, 3H) ppm.

Example 8

1-[3,6-Dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]propan-1-

10 one

A solution of 3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine-4-carbonitrile (200 mg, 0.690 mmol) in 1 ml benzene was added to a solution of ethylmagnesiumbromide (1M, 1.5 ml, 1.5 mmol) in 4 ml benzene at room temperature after stirring at room temperature for 10 minutes. The reaction mixture was quenched with 2 N hydrogen chloride and stirred for 5 minutes, worked up with water, neutralized with 2 N sodium hydroxide, and extracted with EtOAc. The organic layer was dried and concentrated to give a yellow oil. The oil was purified through silica gel column chromatography using 5% EtOAc in hexane as eluent to give 118 mg of the title compound as a yellow solid, mp 117-118°C; IR (KBr) 2980, 2923, 1691, 1573, 1502.


20

-23-

CLAIMS

1. A compound of the formula

5



and the pharmaceutically acceptable acid addition salts thereof, wherein

10

A is N or -CR₆;

B is -NR₁R₂, -CR₁R₂R₁₁, -C(=CR₂R₁₂)R₁, -NHCHR₁R₂, -OCHR₁R₂, -SCHR₁R₂, -CHR₂OR₁₂, -CHR₂SR₁₂, -C(S)R₁ or -C(O)R₁;

15

R₁ is C₁-C₆ alkyl which may optionally be substituted with one or two substituents independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, -O-CO-(C₁-C₄ alkyl), -O-CO-NH(C₁-C₄ alkyl), -O-CO-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -NH(C₁-C₄ alkyl), -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -S(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)CO(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), CN, NO₂, -SO(C₁-C₄ alkyl), -SO₂(C₁-C₄ alkyl), and wherein any of the foregoing C₁-C₄ alkyl and C₁-C₆ alkyl groups may optionally contain

20

one carbon-carbon double or triple bond;

25

R₂ is C₁-C₁₂ alkyl, aryl, -(C₁-C₄ alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, oxazolyl, or benzoxazolyl; or 3- to 8- membered cycloalkyl or -(C₁-C₆ alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C₁-C₆ alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N-Z wherein Z is hydrogen; or C₁-C₄ alkyl, and wherein each of said groups R₂ may optionally be

30

substituted with from one to three substituents independently selected from chloro, fluoro, and C₁-C₄ alkyl, or by one substituent selected from bromo, iodo, C₁-C₆ alkoxy, -O-CO-(C₁-C₆ alkyl), -S(C₁-C₆ alkyl), -COO(C₁-C₄ alkyl), CN, NO₂, -SO(C₁-C₄ alkyl), and

-24-

-SO₂(C₁-C₄ alkyl), and where in said C₁-C₁₂ alkyl and the C₁-C₄ alkyl moiety of said (C₁-C₄ alkylene)aryl may optionally contain one carbon-carbon double or triple bond;

or -NR₁R₂ may form a saturated 5- to 8-membered heterocyclic ring, or -CHR₁R₂ may form a saturated 5- to 8-membered carbocyclic ring, wherein each of these rings
 5 may optionally contain one or two carbon-carbon double bonds and wherein one or two of the carbon atoms of each of these rings may optionally be replaced with a sulfur or oxygen atom;

R₃ is C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, -CH₂OH, -CH₂OCH₃, -O(C₁-C₃ alkyl), -S(C₁-C₃ alkyl), or -SO₂(C₁-C₃ alkyl), wherein said C₁-C₃ alkyl may optionally
 10 contain one carbon-carbon double or triple bond;

R₄ is hydrogen, C₁-C₆ alkyl, fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, amino, -NHCH₃, -N(CH₃)₂, -CH₂OH, -CH₂OCH₃, or -SO_n(C₁-C₄ alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, -CO(C₁-C₄ alkyl), -CHO, or -COO(C₁-C₄ alkyl) wherein the C₁-C₄ alkyl moieties in the foregoing R₄ groups may optionally contain one carbon-carbon double
 15 or triple bond;

R₅ is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, pyrimidyl, benzofuranyl, pyrazinyl or benzothiazolyl, wherein each one of said groups R₅ may optionally be substituted with from one to three substituents independently selected from fluoro, chloro, C₁-C₆ alkyl and C₁-C₆ alkoxy, or by one substituent selected from iodo, hydroxy, bromo, formyl, cyano, nitro, amino, trifluoromethyl, -NH(C₁-C₄ alkyl), -N(C₁-C₆)(C₁-C₂ alkyl), -COO(C₁-C₄ alkyl), -CO(C₁-C₄ alkyl), -COOH, -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -SO₂NH₂, -NHSO₂(C₁-C₄ alkyl), -S(C₁-C₆ alkyl) and -SO₂(C₁-C₆ alkyl), wherein each of said C₁-C₄ alkyl and C₁-C₆ alkyl moieties in the foregoing R₅ groups may optionally be substituted with one to three fluorine atoms;

25 R₆ is hydrogen, C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, -CH₂OH, -CH₂OCH₃, or C₁-C₄ alkoxy;

R₇ is hydrogen, C₁-C₄ alkyl, fluoro, chloro, bromo, iodo, -O(C₁-C₄ alkyl), cyano, -CH₂OH, -CH₂O(C₁-C₂ alkyl), -CO(C₁-C₂ alkyl), or -COO(C₁-C₂ alkyl);

R₁₁ is hydrogen, hydroxy, fluoro, or methoxy; and

30 R₁₂ is hydrogen or C₁-C₄ alkyl;

with the proviso that when A is N, then: (a) B is not unsubstituted alkyl; (b) R₅ is not unsubstituted phenyl or monosubstituted phenyl; and (c) R₃ is not unsubstituted alkyl;

-25-

or a pharmaceutically acceptable salt of such compound.

2. A compound according to claim 1, wherein B is $-NR_1R_2$, $-NHCHR_1R_2$, $-CR_1R_2R_{11}$, or $-OCHR_1R_2$; R_1 is C_1 - C_4 alkyl, which may optionally be substituted with one hydroxy, fluoro or C_1 - C_2 alkoxy group and may optionally contain one carbon-carbon double or triple bond; R_2 is benzyl or C_1 - C_6 alkyl which may optionally contain one carbon-carbon double or triple bond, wherein said C_1 - C_6 alkyl or the phenyl moiety of said benzyl may optionally be substituted with fluoro, C_1 - C_2 alkyl, or C_1 - C_2 alkoxy; and R_{11} is hydrogen or fluoro.
3. A compound according to claim 1, wherein B is tetrahydrofuranyl, tetrahydrothienyl or thiazolidinyl.
4. A compound according to claim 1, wherein R_1 is C_1 - C_4 alkyl substituted with hydroxy.
5. A compound according to claim 1, wherein R_1 and R_2 each independently are C_1 - C_4 alkyl which may optionally be substituted with fluoro, C_1 - C_2 alkyl or C_1 - C_2 alkoxy and may optionally contain one carbon-carbon double or triple bond.
6. A compound according to claim 1, wherein B is $-NR_1R_2$, and wherein $-NR_1R_2$ form a thiazolidinyl ring, or B is $-NHCHR_1R_2$ or $-OCHR_1R_2$, wherein the CHR_1R_2 moiety of said $-NHCHR_1R_2$ or $-OCHR_1R_2$ forms a tetrahydrofuranyl or tetrahydrothienyl ring.
7. A compound according to claim 1, wherein R_3 is methyl, chloro, or methoxy.
8. A compound according to claim 1, wherein R_4 and R_6 are, independently, hydrogen, methyl or chloro, with the proviso that R_4 and R_6 are not both hydrogen.
9. A compound according to claim 1, wherein: (a) R_3 is methyl, chloro, or methoxy; (b) R_4 and R_6 are each, independently, hydrogen, methyl, ethyl, or chloro, and R_4 and R_6 are not both hydrogen; and (c) R_5 is phenyl substituted by two or three substituents independently selected from fluoro, chloro, bromo, iodo, C_1 - C_4 alkoxy, trifluoromethyl, C_1 - C_6 alkyl which may optionally be substituted by one of hydroxy, C_1 - C_4 alkoxy and fluoro and which may optionally contain one double or triple bond, $-(C_1$ - C_4 alkylene) $O(C_1$ - C_2 alkyl), C_1 - C_3 hydroxyalkyl, hydroxy, formyl, $-COO(C_1$ - C_2 alkyl), and $-(C(O)(C_1$ - C_4 alkyl).

-26-

10. A compound according to claim 1, wherein R_5 is phenyl substituted with two or three substituents independently selected from fluoro, chloro, bromo, iodo, C_1 - C_4 alkoxy, trifluoromethyl, C_1 - C_6 alkyl which may be substituted by one of hydroxy, C_1 - C_4 alkoxy and fluoro and may optionally contain one carbon-carbon double or triple bond,
 5 $-(C_1$ - C_4 alkylene) $O(C_1$ - C_2 alkyl), C_1 - C_3 hydroxyalkyl, hydroxy, formyl, $COO(C_1$ - C_2 alkyl) and $-C(O)(C_1$ - C_4 alkyl).

11. A compound according to claim 1, wherein said compound is
 butyl-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-
 ethylamine;
 10 [3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4,b]pyridin-4-yl]-(1-methoxymethylpropyl)-amine;
 4-(1-methoxymethylpropoxy)-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine;
 (1-ethylpropyl)-[3,5,6-trimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-
 15 4-yl]-amine;
 4-(1-ethylpropoxy)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-b]pyridine;
 4-(1-ethylpropoxy)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-b]pyridine; or
 20 4-(1-ethylpropoxy)-2,5-dimethyl-7-(2,6-dimethyl-4-bromophenyl)-7H-pyrrolo[2,3-b]pyridine; or a pharmaceutically acceptable salt of one of the foregoing compounds.

12. A pharmaceutical composition for the treatment of: (a) a disorder the treatment of which is effected or facilitated by antagonizing CRF; or (b) a disorder selected from inflammatory disorders; generalized anxiety disorder; panic; phobias;
 25 obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception; mood disorders; depression; dysthemia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer; irritable bowel syndrome; Crohn's disease; spastic colon; immune dysfunction; human immunodeficiency virus (HIV) infections; neurodegenerative diseases; Alzheimer's disease;
 30 Parkinson's disease; Huntington's disease; gastrointestinal diseases; eating disorders; hemorrhagic strokes; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiuretic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage; excitotoxic neuronal damage;

-27-


pilepsy; stroke; muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; chemical dependencies and addictions; drug and alcohol withdrawal symptoms; and hypoglycemia in a mammal, comprising an amount of a compound according to claim 1 that is effective in the treatment of said disorder, and a pharmaceutically acceptable carrier.

13. A method for the treatment of: (a) a disorder the treatment of which is effected or facilitated by antagonizing CRF; or (b) a disorder selected from inflammatory disorders; generalized anxiety disorder; panic; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception; mood disorders; depression; dysthymia; bipolar disorders; cyclothymia; fatigue syndrome; headache; cancer; irritable bowel syndrome; Crohn's disease; spastic colon; immune dysfunction; human immunodeficiency virus (HIV) infections; neurodegenerative diseases; gastrointestinal diseases; eating disorders; hemorrhagic stress; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage excitotoxic neuronal damage; epilepsy; stroke; stress induced immune dysfunctions; muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; chemical dependencies and addictions; drug and alcohol withdrawal symptoms; and hypoglycemia in a mammal, comprising administering to a subject in need of said treatment an amount of a compound according to claim 1 that is effective in treating such disorder.

14. A compound of the formula

25

30



II

wherein A is N or -CR₆;

D is chloro, hydroxy or cyano;

-28-

R_{19} is methyl, ethyl or chloro;

R_3 is C_1 - C_4 alkyl, fluoro, chloro, bromo, iodo, $-CH_2OH$, $-CH_2OCH_3$, $-O(C_1-C_3 \text{ alkyl})$, $-S(C_1-C_3 \text{ alkyl})$, or $-SO_2(C_1-C_3 \text{ alkyl})$, wherein said C_1 - C_3 alkyl may optionally contain one carbon-carbon double or triple bond;

- 5 R_4 is hydrogen, C_1 - C_6 alkyl, fluoro, chloro, bromo, iodo, C_1 - C_4 alkoxy, amino, $-NHCH_3$, $-N(CH_3)_2$, $-CH_2OH$, $-CH_2OCH_3$, or $-SO_n(C_1-C_4 \text{ alkyl})$, wherein n is 0, 1 or 2, cyano, hydroxy, $-CO(C_1-C_4 \text{ alkyl})$, $-CHO$, or $-COO(C_1-C_4 \text{ alkyl})$ wherein the C_1 - C_4 alkyl moieties in the foregoing R_4 groups may optionally contain one carbon-carbon double or triple bond;

- 10 R_5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, pyrimidyl, benzofuranyl, pyrazinyl or benzothiazolyl, wherein each one of said groups R_5 may optionally be substituted with from one to three substituents independently selected from fluoro, chloro, C_1 - C_6 alkyl and C_1 - C_6 alkoxy, or by one substituent selected from iodo, hydroxy, bromo, formyl, cyano, nitro, amino, trifluoromethyl, $-NH(C_1-C_4 \text{ alkyl})$, $-N(C_1-C_6)(C_1-C_2$
 15 $\text{alkyl})$, $-COO(C_1-C_4 \text{ alkyl})$, $-CO(C_1-C_4 \text{ alkyl})$, $-COOH$, $-SO_2NH(C_1-C_4 \text{ alkyl})$, $-SO_2N(C_1-C_4 \text{ alkyl})(C_1-C_2 \text{ alkyl})$, $-SO_2NH_2$, $-NHSO_2(C_1-C_4 \text{ alkyl})$, $-S(C_1-C_6 \text{ alkyl})$ and $-SO_2(C_1-C_6 \text{ alkyl})$, wherein each of said C_1 - C_4 alkyl and C_1 - C_6 alkyl moieties in the foregoing R^5 groups may optionally be substituted with one to three fluorine atoms;

- R_6 is hydrogen, C_1 - C_4 alkyl, fluoro, chloro, bromo, iodo, $-CH_2OH$, $-CH_2OCH_3$, or
 20 C_1 - C_4 alkoxy; and

R_7 is hydrogen, C_1 - C_4 alkyl, fluoro, chloro, bromo, iodo, $-O(C_1-C_4 \text{ alkyl})$, cyano, $-CH_2OH$, $-CH_2O(C_1-C_2 \text{ alkyl})$, $-CO(C_1-C_2 \text{ alkyl})$, or $-COO(C_1-C_2 \text{ alkyl})$;

with the proviso that when A is N , R_5 is not unsubstituted phenyl and R_{19} is not unsubstituted alkyl.

INTERNATIONAL SEARCH REPORT

Inter. nal Application No
PCT/IB 95/00373

A. CLASSIFICATION / SUBJECT MATTER
IPC 6 C07D471/04 A61K31/435 //(C07D471/04,221:00,209:00),
(C07D471/04,231:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,3 925 388 (HOEHN ET AL.) 9 December 1975 see column 1, line 10 - column 2, line 5; column 7, line 44 - column 8, line 24 ---	1,12
A	CHEMICAL ABSTRACTS, vol. 82, no. 9, 1975 Columbus, Ohio, US; abstract no. 57581n, L. N. YAKHONTOV ET AL. 'Azaindole derivatives. XLVII. Synthesis and pharmacological study of 3-aminoalkyl derivatives of azaindoles.' page 562; see abstract & KHIM.-FARM. ZH. , vol. 8, no. 11, 1974 --- -/--	1,12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

17 July 1995

Date of mailing of the international search report

25. 07. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

Int. .onal Application No

PCT/IB 95/00373

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO,A,94 13677 (PFIZER) 23 June 1994 see claims 1,11 -----	1,12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 95/00373

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 13 is directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Int. .onal Application No

PCT/IB 95/00373

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-3925388	09-12-75	AU-B- 462839	10-07-75
		AU-A- 4514672	07-02-74
		BE-A- 787249	05-02-73
		CA-A- 997350	21-09-76
		CA-A- 997352	21-09-76
		CH-A- 553800	13-09-74
		CH-A- 549590	31-05-74
		CH-A- 553798	13-09-74
		DE-A- 2237765	08-02-73
		FR-A,B 2150737	13-04-73
		GB-A- 1402172	06-08-75
		JP-C- 1152313	30-06-83
		JP-A- 56022784	03-03-81
		JP-B- 57045440	28-09-82
		JP-C- 1246878	16-01-85
		JP-A- 56022768	03-03-81
		JP-B- 59007703	20-02-84
		NL-A- 7210701	07-02-73
		US-A- 3833594	03-09-74
		US-A- 3856799	24-12-74
		US-A- 3755340	28-08-73
WO-A-9413677	23-06-94	AU-B- 5728194	04-07-94
		CN-A- 1094048	26-10-94
		FI-A- 935675	18-06-94